Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
"The thrill of victory and the agony of defeat."
That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (NASDAQ: CRSP) and (NYSE: PFE) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.
But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the arguments for CRISPR Therapeutics and Pfizer, respectively.
Source Fool.com
Pfizer Inc. Stock
€25.77
0.140%
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 59.1% compared to the current price of 25.77 € for Pfizer Inc..
